Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Presentations at Upcoming AACR-NCI-EORTC Anticancer Conference
First clinical data to be reported for SAR566658 , further expanding the extensive body of data reported with ImmunoGen's maytansinoid antibody-drug conjugate (ADC) technology. Presentations on new ADC technologies, including a new class of payload agents, highlight ImmunoGen's continuing
View HTML
Toggle Summary ImmunoGen, Inc. Announces New License Agreement
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Novartis has licensed the exclusive right to use the Company's ADC technology to develop
View HTML
Toggle Summary ImmunoGen, Inc. Announces Results from Kadcyla® Phase III Trial, TH3RESA, Being Presented Today at the European Cancer Congress
Roche's Kadcyla found to significantly extend duration of progression-free survival in patients with advanced HER2-positive breast cancer in second large randomized trial. Kadcyla comprises Roche's trastuzumab antibody and ImmunoGen's ADC technology; it has been approved for marketing in several
View HTML
Toggle Summary ImmunoGen, Inc. Announces Positive Regulatory Decisions for Roche's Kadcyla® in the European Union and Japan
CHMP has issued a positive opinion for Kadcyla, with the European Commission decision expected by the end of 2013. The Japanese MHLW has approved Kadcyla for marketing in Japan , which triggers a $5 million milestone payment to ImmunoGen. Kadcyla comprises Roche's trastuzumab antibody and
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor
View HTML
Toggle Summary ImmunoGen, Inc. Announces Executive Change
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that Gregory D. Perry , Executive Vice President and Chief Financial Officer, has
View HTML